Standardisation of EGFR FISH in colorectal cancer: results of an international interlabatory reproducibility ring study

Andrea Sartore-Bianchi,1 Steffen Fieuws,2 Silvio Veronese,3 Mauro Moroni,1 Nicola Personeni,4 Milo Frattini,5 Valter Torri,6 Federico Cappuzzo,4 Sara Vander Borght,7 Vittoria Martin,5 Margaret Skokan,6 Armando Santoro,4 Marcello Gambacorta,3 Sabine Teijpar,9 Marileila Varella-Garcia,8 Salvatore Siena1

ABSTRACT

Aims Epidermal growth factor receptor (EGFR) gene copy number evaluated by fluorescence in situ hybridisation (FISH) can discriminate among KRAS wild-type patients those with better outcome to EGFR-targeted therapy in metastatic colorectal cancer, further enhancing selection of patients. Nevertheless, enumeration of gene copies is challenging and the lack of analytical standardisation has limited incorporation of the test into the clinical practice. We therefore assessed EGFR FISH interlaboratory consensus among five molecular diagnostic reference centres.

Methods A set of 12 colorectal cancer samples circulated among laboratories, and samples were scored according to commonly agreed guidelines. Reproducibility was quantified using the standard error of measurement (SEM).

Results A SEM of 0.865 and a within-subject coefficient of variation (WSCV) of 26.8% for mean EGFR gene/nuclei and a SEM of 0.235 and a WSCV of 19.4% for the mean EGFR gene/CEP7 ratio were observed. Measurement of the fraction of cells displaying chromosome 7 polysomy showed WSCV of 46.6%, 34.0% and 51.0% for percentage of cells displaying ≥2, ≥3 and ≥4 EGFR signals, respectively. Among different slides of the same specimen, the WSCV was 6.1% for mean EGFR gene/nuclei and 3.9% for mean of EGFR gene/CEP7 ratios.

Conclusions Molecular diagnosis of EGFR gene copy number by FISH varied largely among pathology centres, with fluctuations covering the whole range of proposed cut-offs of predictive usefulness from literature. Definition of a detailed scoring system and implementation of comprehensive training programmes for laboratories are therefore necessary before including the test into clinical practice.

INTRODUCTION

Targeted therapy of metastatic colorectal cancer (mCRC) with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs) cetuximab or panitumumab has been revolutionised by the introduction of genetic profiling of individual tumours. Although initial response rates of about 10% were seen in patients with chemotherapy refractory mCRC, it was subsequently discovered that higher response rates in the range of 13%—17% were achievable in tumours without mutations in codon 12 or 13 of the KRAS gene, whereas only 0%—1.2% of the KRAS mutant tumours responded to therapy.1,2 Nevertheless, even in KRAS wild-type CRCs, about 40% of the previously untreated3–5 and about 60%—70% of the previously treated6,7 do not respond to anti-EGFR treatment and additional detection of NRAS, BRAF and PIK3CA exon 20 mutations8 and loss of PTEN protein9 or better discrimination among KRAS mutations by excluding G13D carriers10 may further enhance selection of patients.

In addition to these negative predictive molecular alterations, the EGFR gene copy number (GCN) stood up as a candidate biomarker for predicting response of CRC to anti-EGFR therapy.11 EGFR GCN could indeed further discriminate among KRAS wild-type patients those better candidates to cetuximab or panitumumab, enhancing patients’ selection by achieving response rates as high as 80%.12–14 This notion has been recently supported also by a study in which a molecularly annotated platform of patient-derived xenografts (‘xenopatients’) was exploited for identifying novel mechanisms of resistance to cetuximab, confirming that EGFR GCN gain (as assessed by quantitative PCR) tended to segregate responders also in this preclinical context.15 Fluorescence in situ hybridisation (FISH) has been used almost invariably in retrospective clinical studies for assessing EGFR GCN in CRC.11 13 14 However, signal enumeration in solid tumour sections by FISH is challenging to interpret16 17 and guidelines dealing with key technical issues and reading strategies like those available for non-small-cell lung cancer18 are not available for CRC. Thus, the lack of standardisation of analytical methods and scoring systems may partly explain why the EGFR GCN testing as a predictive biomarker has not been incorporated into the clinical practice yet.

We therefore designed this international ring study in order to assess interlaboratory consensus in EGFR copy number enumeration among five highly experienced molecular diagnostic centres with the aim of establishing variability in scoring and identifying issues that may contribute to discordant results.

MATERIAL AND METHODS

Study design

A slide-exchange programme was used to compare EGFR GCN FISH testing results among five pathology reference centres located in Belgium.
Specimen selection and logistics

Tumour samples were selected by the coordinating laboratory from anonymised CRC surgical specimens in such way to represent different FISH patterns. All samples were fixed with 10% neutral buffered formalin (12–48 h) and embedded into paraffin blocks. Tissue sections (4 μm thick) were mounted on positively charged glass slides with similar orientation and 25 slides were prepared from each of the 12 tumour specimens selected. Five slides from each specimen were then sent to each of the other four testing centres in a blinded manner, while five remaining slides from each specimen were retained by the sending laboratory for its own evaluation. Sequential slides were numbered following the scheme: laboratory A, slides 1, 6, 11, 16, 21 (the last one stained with H&E for morphology), laboratory B, slides 2, 7, 12, 17, 22 and so on for the other three laboratories.

Specimen analysis

FISH assays were performed by each testing centre using the EGFR/CEP7 FISH Probe Kit (Abbott Molecular, Des Plaines, Illinois, USA), according to its own operating protocol as previously described. The equipment used in each laboratory was the following: ZEISS Z 1 microscope with high-resolution camera and full Metasystem software (Ospedale Niguarda Ca’ Granda, Milano, Italy), ZEISS Axioplan 2 microscope with Metasystems CCD camera and ISIS software from Metasystems (University Hospital Gasthausberg, Leuven, Belgium), Olympus BX 61 microscope with high-resolution camera and Applied Imaging CytoVision Genus software (Istituto Clinico Humanitas, Rozzano, Italy), ZEISS Axiioskop 2 plus microscope with high-resolution camera and AxioVision software from ZEISS (Istituto Cantonale di Patologia, Locarno, Switzerland) and ZEISS Axiolmager Z1 microscope with CCD camera and CytoVysion/Genus software from Leica Microsystems (University of Colorado School of Medicine, Aurora, Colorado, USA). Analysis was performed according to guidelines commonly agreed by laboratory directors followed by distribution of written instructions including details on how to (1) assess quality of specimen for analyses, (2) select eight tumour foci per specimen, (3) select nuclei for scoring, (4) count the signals in each nucleus and (5) define gene amplification (online supplementary document 1). Analyses in individual cells were reported in electronic worksheets for each individual specimen and subsequently sent to statisticians for analysis. FISH scores were based on counting of $EGFR/CEP7$ signals measured as: (1) mean $EGFR$ signals per nucleus, (2) mean $EGFR/mean\ CEPI7$ ratio, (3) mean of percentage of cells displaying $\leq2$ $EGFR$ signals, (4) mean of percentage of cells displaying $\leq3$ $EGFR$ signals and (5) mean of percentage of cells displaying $\geq4$ $EGFR$ signals. An additional testing was performed by one of participating centres (University Hospital Gasthausberg, Leuven, Belgium) analysing intralaboratory reproducibility of FISH assay among different slides of the same specimen.

Statistical analysis

The reproducibility among laboratories was quantified using the standard error of measurement (SEM), which is the SD of the values within a specimen. If all laboratories assign the same value to a patient, the SEM equals 0. A SEM equal to 0.5 implies that for a specific patient, 95% of the obtained values (from various laboratories) are expected to fall in a range of $\pm1.96 \times 0.5$ around the true value $= [-1; +1]$. Furthermore, the differences in values between two laboratories are expected to fall in the range $\pm 1.96 \times \sqrt{0.5^2 + 0.5^2} = [-1.39; 1.39]$. The SEM also has been expressed relative to the mean of the values, which is known as the within-subject (specimen) coefficient of variation (WSCV). These indices reflect different sources of variability, that is, differences between laboratories (and/or observers), differences between slides within a specimen and measurement error. In the between-slides variability performed on the same specimen, the SEM and WSCV reflect only between-slide variability and measurement error. Mean $EGFR$/nucleus signals have been also categorised according to the following cut-offs: (1) from 0 to $\leq2$, (2) between 2 and $\leq3$ and (3) $\geq3$. The interlaboratory agreement for this categorisation was assessed using a (weighted) $k$ coefficient for multiple raters.

RESULTS

As depicted in figures 2 and 3, scoring of mean $EGFR$ GCN per nucleus (defining absolute $EGFR$ GCN of a given sample) and $EGFR/CEP7$ ratio (defining $EGFR$ status relative to the number of copies of chromosome 7 centromere and discriminating disomy, aneusomy or amplification) showed a low level of consensus among centres for both parameters. For mean $EGFR$ gene per nucleus, SEM was 0.865, thus indicating, with a mean value of 3.22, a WSCV of 26.8%. This denotes that these

![Figure 1](http://jcp.bmj.com/fig/12136/jclinpath-2011-200353.png)
different laboratories evaluate a given patient, 95% of the measurements would be expected to fall in the range between values being 52.5% (\( \pm 1.96 \times 26.8\% \)) lower and 52.5% higher than the true value. As an example, for a patient with a true value of 3.22, the 95% range would be between 1.53 and 4.92. For the mean \( \text{EGFR} \)/CEP7 ratio, the WSCV was 19.4% (SEM=0.235). A trend towards having higher variability was noticeable in specimens with higher \( \text{EGFR} \) copy number.

Since it was proposed that \( \text{EGFR} \) GCN could be proficiently scored not only as mean \( \text{EGFR} \) GCN/nucleus but also in terms of fraction of chromosome 7 polysomy within the tumour specimen, we additionally elected to test consensus among laboratories according to the \( \text{EGFR} \)/CEP7 ratio. Similarly to mean \( \text{EGFR} \) GCN/nucleus, this parameter was associated with high variation, showing WPCV of 46.6%, 34.0% and 51.0% for percentage of cells displaying \( \leq 2, \geq 3 \) and \( \geq 4 \) \( \text{EGFR} \) signals, respectively (figure 4).
Finally, consensus analysis was supported by a non-parametric approach, by ordering data of mean EGFR gene per nuclei according to the following cut-offs for EGFR GCN per nuclei: (1) from 0 to ≤2, (2) between 2 and ≤3 and (3) >3 (table 1). In accordance with previous results, category ratings analysis indicated a low level of agreement among laboratories (κ=0.202, SE=0.072).

**Analysis of FISH concordance within tumour specimens**

Given the potential tumour heterogeneity of EGFR GCN within samples, an additional testing was performed analysing intralaboratory reproducibility of FISH assay among different slides of the same specimen. As depicted in figure 5, the WSCV was 6.1% for mean EGFR gene per nuclei and 3.9% for mean of EGFR/CEP7 ratios, hence accounting only for a small fraction of the observed interlaboratory disagreement. Evaluation of fraction of chromosome 7 polysomy within the same tumour specimen resulted in WSCV of 10.5%, 12.4% and 24.0% for the % of cells displaying ≥2, ≥3 and ≥4 EGFR signals, respectively (data not shown).

**DISCUSSION**

EGFR GCN has been proposed from several studies as a candidate biomarker for predicting response of CRC to anti-EGFR therapy by discriminating among KRAS wild-type patients those better candidates to cetuximab or panitumumab, thus enhancing patients’ selection. Nevertheless, these data come from retrospective analyses of patients’ cohorts and there is not a reference technique for scoring. EGFR gene status deregulation due to true amplification, defined as more than a doubling of the EGFR gene compared with the CEP7 copy number, rarely occurs in CRCs. Therefore, correlation with response has been mainly based on an increase in EGFR gene dosage caused by chromosome 7 polysomy, even though it is unknown whether balanced polysomy could have an equivalent biologic effect as compared with gene amplification in driving cancer progression and thus predicting response to EGFR-targeted agents. Discrepant cut-offs, in the range of 2.5—2.92 copies per cell, were proposed for discriminating responders from non-responders. Results of this slide-exchange ring study show that, even under standardised conditions by means of shared written guidelines and among highly experienced pathology centres, there was a low level of consensus for enumerating EGFR copy number in FISH assays in mCRC and that the observed variability in scoring translates into fluctuations alongside the whole range of marker usefulness. Subcategorisation of disomy (figure 4), which was recently reported to be associated with lack of response to cetuximab, did not improve reproducibility in our study. The study also suggests that discordant data are not due to tumour heterogeneity within samples but that the major factors for the lack of consensus should be technical, like the quality of the slide, the equipment used for the analyses and the personnel difference in interpretation of the guidelines. In this study, guidelines were discussed

---

Table 1 Distribution of category ratings (top) and relative frequencies (bottom) of mean EGFR gene copy number in participating laboratories according to the following cut-offs: (1) from 0 to ≤2, (2) between 2 and ≤3 and (3) >3 (κ=0.20168, SE=0.072)

| Ratings* | Patient | Colorado (%) | Rozzano (%) | Locarno (%) | Leuven (%) | Milano (%) |
|----------|---------|--------------|-------------|-------------|------------|------------|
| 0        | 1       | 3            | 3           | 3           | 3          |
| 1        | 2       | 3            | 2           | 3           | 3          |
| 2        | 3       | 3            | 2           | 2           | 2          |
| 3        | 4       | 3            | 3           | 3           | 3          |
| 4        | 5       | 3            | 2           | 1           | 1          |
| 5        | 6       | 3            | 3           | 3           | 3          |
| 6        | 7       | 3            | 2           | 1           | 1          |
| 7        | 8       | 3            | 2           | 1           | 1          |
| 8        | 9       | 3            | 3           | 1           | 1          |
| 9        | 10      | 2            | 2           | 1           | 1          |
| 10       | 11      | 2            | 1           | 2           | 2          |
| 11       | 12      | 2            | 2           | 1           | 2          |

Frequencies

| Rating | Colorado (%) | Rozzano (%) | Locarno (%) | Leuven (%) | Milano (%) |
|--------|--------------|-------------|-------------|------------|------------|
| 0      | 1            | 3           | 3           | 3          |
| 1      | 0            | 8.3         | 0           | 25.0       | 25.0       |
| 2      | 3            | 5           | 4           | 5          |
| 3      | 25.0         | 66.7        | 41.7        | 33.3       | 41.7       |
| 4      | 3            | 7           | 5           | 4          |
| 5      | 75.0         | 25.0        | 58.3        | 41.7       | 33.3       |

*Rating, categories: (1) 0 to ≤2, (2) 2 to ≤3 and (3) >3. EGFR, epidermal growth factor receptor.

---

**Figure 5** Intra-laboratory reproducibility of fluorescence in situ hybridisation assay among different slides of the same specimen evaluating mean epidermal growth factor receptor (EGFR) gene per nuclei (A) and mean ratio of EGFR/CEP7 (B). Each dot represents the scorings obtained on one slide for each of the 12 specimens. The specimens are ordered according to their mean score. SEM, standard error of measurement (within slide SD). To represent the ratios appropriately, the y-axis is on a logarithmic (base 2) scale. WSCV = within sample coefficient of variation, that is, the SEM expressed relatively to the mean value.
and agreed upon by the laboratory directors and implemented, but a preliminary exchange of a training set of slides for refining interpretation could have helped in improving reproducibility. We assumed indeed ‘a priori’ that all laboratories involved in the study had the same experience and would have had similar interpretation of the guidelines, but there are many relevant skills necessary to perform enumeration of GCN in solid tumours, including identification of tumour versus non-tumour cells, focus across full depth of the section to account for complete nuclear area and, very important in CRC sections, identification of the correct individual nucleus since the individual cells may be diffusely overlapped. From this study, we learnt that in order to reach reproducible levels for all the variables explored, this strategy was not enough and that enumeration of GCN by FISH requires more intensive training to be reproducible among laboratories. For these reasons, a preliminary test of a subset of tumours according to the drafted guidelines in a process of ‘familiarisation’ would help by confirming that involved laboratories are doing hybridisation at the same quality level and applying same interpretation to the guidelines. The use of familiarisation for testing EGFR by FISH in non-small-cell lung cancer does indeed support this alternative strategy (Marileila Varella-Garcia, personal communication).

Various reports applied alternative assays for determination of EGFR copy number gain in mCRC, such as chromogenic in situ hybridisation,$^{15, 28}$ silver in situ hybridisation (SISH),$^{27}$ and quantitative real-time PCR.$^{15, 28}$ Chromogenic in situ hybridisation and SISH, if scored manually, will have at least the same limitations of FISH, although enabling simultaneous morphological tissue characterisation which could facilitate interpretation. Quantitative PCR also has limitations, both due to the poor quality of material extracted from formalin-fixed paraffin-embedded sections and the fact that genomic regions used for control may be involved in losses or gains therefore impairing the estimative of the level of gain for the test gene. Furthermore, tumour DNA dilution by healthy cells during DNA extraction can affect results of this assay. Methods to improve GCN enumeration could therefore include automation of scoring by means of software enhancing statistical power that are already available for FISH and SISH. However, automated software analysis does not work well for colorectal histology because of the irregular shape of colon cancer cells, the admixture with surrounding stroma and the need to distinguish malignant cells from normal colonic cells. These systems work better indeed for tumours with large tumour nests and for assays based on a ratio between two probes (such as HER2/CENP17 in breast cancer) than for pure enumeration of GCN since the ratio is not affected by correctly identifying the contours of individual cells. Finally, since there is a poor correlation between EGFRIHC and GCN,$^{17, 26, 28}$ further studies addressing whether in situ hybridisation techniques could be effectively guided by preliminary or synchronous IHC—and thus performed in areas with high EGFR IHC staining—should be warranted.

In conclusion, implementation of a comprehensive programme for standardisation of protocol and guidelines for EGFR GCN detection in mCRC is warranted in order to enhance reproducibility and subsequent dissemination into the clinic as a biomarker for predicting outcome to EGFR-targeted therapies. Such programme should be performed by setting up a larger follow-up study to address more in depth each parameter taken into consideration in present study in a larger sample size. A uniform protocol should be used since current results already show that existing literature cut-offs cannot be implemented and the programme should deliver not only written protocols and instructions but also technical training, possibly coupled with a familiarisation preliminary phase. Periodical proficiency testing should also be required from the clinical laboratories offering the test as a predictive assay for selecting patients.

**Funding** This work was supported by Oncologia Ca’ Granda ONLUS Fondazione and Associazione Italiana per la Ricerca sul Cancro (AIRC); Investigator Grant 4412 and 2010 Special Program Molecular Clinical Oncology 5 × 1000, project 9970.

**Competing interests** AS-B: following relevant financial activities outside the submitted work: payment for board membership (AMGEN); payment for lectures including service on speakers bureaus (AMGEN, Merck-Serono). FC: following relevant financial activities outside the submitted work: payment for consultancy (Roche). MV-G: following relevant financial activities outside the submitted work: payment to my Institution (University of Colorado) as co-inventor in a patent to use EGFR biomarker for selection of non-small-cell lung cancer patients to EGFR inhibitors therapy. SS: following relevant financial activities outside the submitted work: payment for Board membership (Roche, Merck-Serono, AMGEN). ST: following relevant financial activities outside the submitted work: payment to my Institution for research grants (Merck-Serono). Other co-authors: none declared.

**Contributors** Conception and design of the study: AS-B, SV, MM, MF, FC, VM, AS, MG, ST, MV-G and SS. Data analysis and interpretation: AS-B, SF, NP, VT, SVB, MS, SV, MM, MF, FC, VM, AS, MG, ST, MV-G and SS. Manuscript writing: AS-B, SF, SV, MM, NP, ST, MV-G and SS. Provision of study material: AS-B, SV, MM and SS. Financial support: SS. The manuscript was approved by all authors.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**REFERENCES**

1. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28:1254–61.
2. Winer E, Gralow J, Diller L, et al. American Society of Clinical Oncology. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2009;27:812—26.
3. Bokemeyer C, Bondarenko I, Makshon A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663—71.
4. Van Cutsem E, Kohne CH, Hiyre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2008;360:1408—17.
5. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697—705.
6. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2009;26:374—8.
7. Moroni M, Veronesi S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antieGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279—86.
8. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy refractory metastatic colorectal cancer: a retrospective cohort analysis. Lancet Oncol 2010;11:753—62.
9. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, et al. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PLoS One 2009;4:e7287.
Moroni M, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812–20.

Stena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009;101:1308–24.

Laurent-Puig P, Cayre A, Manceau G, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2006;24:2924–30.

Scartozzi M, Bearzi I, Mandolesi A, et al. Epidermal Growth Factor Receptor (EGFR) gene copy number (GGN) correlates with clinical activity of irinotecan cetuximab in K-RAS wildtype colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer 2009;9:303.

Li YH, Wong F, Shen L, et al. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients. Clin Cancer Res 2011;17:890–90.

Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discovery. Published Online First: 2 September 2011. doi:10.1158/2159-8290.CD-11-0109.

Moroni M, Sartore-Bianchi A, Veronesi S, et al. EGFR FISH in colorectal cancer: what is the current reality? Lancet Oncol 2008;9:402–3.

Martin V, Mezzuzehelli L, Frattini M. An overview of the epidermal growth factor receptor fluorescent in situ hybridisation challenge in tumour pathology. J Clin Pathol 2009;62:314–24.

Varella-Garcia M, Diebold J, Eberhard DA, et al. EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009;62:970–7.

Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007;97:1139–45.
Figure 3  (A) An example of aspirated material from a cystic brain lesion, clinicoradiologically suspected to be a neoplasm, prepared into a cell block using the method as described. (B) The yield from the cystic material is ample, with excellent cytomorphological preservation, allowing a diagnosis of an inflammatory non-neoplastic lesion.

Figure 4  Scoring of epidermal growth factor receptor (EGFR) gene copy number was also performed according to the fraction of chromosome 7 polysomy within tumour specimens, adopting a cut-off of percentage of cells displaying $\leq 2$ signals (A), $\geq 3$ signals (B) or $\geq 4$ signals (C). As in previous graphics, each line represents the scorings of one laboratory given for each of the 12 specimens. The specimens are ordered according to their mean score. SEM, SE of measurement (= within patient SD). WSCV, within-subject coefficient of variation, that is the SEM expressed relatively to the mean value.
The EGFR FISH Assay in Metastatic Colorectal Carcinoma: A Practical Guide for Analysis and Interpretation

Goal:
Standardization and Reproducibility of EGFR FISH assay among laboratories
Aspects to be Addressed

I. Specimen Preparation
II. Assay conditions and Instruments
III. Criteria for Microscope Analysis
   Quality Assessment
   Selection of Tumor Foci
   Selection of Nuclei to Score
   Imaging for Permanent Record
IV. Signal Enumeration and Recording
   Counting Signals
   Defining Gene Amplification
V. Definition of FISH pattern and Reporting
I. Specimen Preparation

Formalin-fixed, paraffin-embedded tissue according to guidelines proposed for HER2 FISH in breast carcinomas

1. **Time from tissue acquisition to fixation**: as short as possible
2. **Tissue fixation**: 6-48 hours in 10% neutral buffered formalin
3. **Storage of fixed tissue**: Protected from light at room temperature
4. **Thickness of sections**: 4µm +/- 1µm
5. **Mounting**: on charged (coated) glass slides, sample attached ~ 1/3 distal to the frosted edge, all slides from each specimen with similar orientation
6. **Section age**: Preferentially freshly cut (<3 months), maintained protected from light at room temperature
7. **Material requested by the FISH laboratory**
   a. One H-E stained and 2 unstained sections,
   b. Preferentially from the diagnostic specimen.
   c. Tumor content confirmed before transfer to FISH laboratory
II. Assay Conditions and Instruments

1. **Probe**: LSI EGFR SpectrumOrange/CEP7 SpectrumGreen (Abbott Molecular)

2. **Protocol**: Flexible as soon as quality of the results is excellent

3. **Microscope features**:
   a. Epifluorescence
   b. Equipped with single band pass filters (TR, FITC, DAPI). Double and triple band pass filters highly desirable
   c. Objectives with high NA

4. **Imaging features**: CCD camera and Z-stacking capability
III. Criteria for Microscope Analyses

A. Quality Assessment of the FISH Specimen

1. Assess the **adequacy of the specimen for analysis** according to the requisites listed below, using high power objectives (40x, 63x or 100x). All requisites must be reached in at least **70% of tumor cells**, otherwise specimen is classified as unsatisfactory and troubleshooting must be performed.

   a. **Use the DAPI filter to verify integrity of the tumor nuclear morphology.** In adequate specimens, chromatin in the tumor cells is not over-treated to the point of preventing clear identification of nuclear border and is not missing from nuclear areas, and tumor nuclei are not covered by a cloudy yellowish layer or obscured by autofluorescent structures.

   b. **Use single and double pass interference filters to inspect quality of the hybridization** in tumor and non-tumor cells (stroma reactive cells, etc). In adequate specimens, green signals (CEP 7) are bright, compact (occasionally slightly stringy or diffuse), oval shapes and red (EGFR) signals are bright, small round shapes, commonly adjacent to CEP 7 signals. The CEP 7 signal is larger and brighter than the EGFR red signal. Signals may not be fuzzy or very patchy.

   c. **Use single and double pass interference filters to inspect the background.** It should appear dark and free of fluorescence particles or haziness.
Adequate Specimen - Passed Quality Assessment
Inadequate Specimens: Quality Assessment Failure

- Poor signal intensity; background haziness
- Missing chromatin
- Cross-hybridization of CEP 7 signals
- Patchy red background
III. Criteria for Microscope Analyses

B. Selection of Tumor Foci: 3 mm strategy for Heterogeneous Tumors

1. Review grossly the H&E and FISH slides searching for areas with tumor material. Select a “starting corner” (for instance, NE), identify a distinct tumor area, switch to the 100x objective and analyze approximately 10 representative cells.
2. Insert back the 40x objective, move the stage 3 mm along the Y (north or south) axis, and in this 2nd location select approximately 10 cells for analysis.
3. To reach the 3rd location, repeat the sequence of steps above. After the 3rd reading in the same axis.
4. For the next 3 locations (4th to 6th), move again the stage 3 mm along the Y axis (north or south) axis.
5. Choose the next 2 locations in different X axis locations, following same schema described, up to complete the 8 tumor areas and 80 tumor cells scored.
6. When the 3 mm strategy leads to a non-tumor area do the following:
   a. Scan the new field ± 1 mm (X or Y) to find a scorable area and resume the previous schema from that point on.
   b. If there is not tumor area close, return to the previous location and attempt moving 3 mm in a different X or Y direction.
   c. If no sufficient tumor area is found within 3 mm of the previously analyzed location, move to a completely different analyzable section of the specimen, score approximately 10 cells and then proceed with the 3 mm strategy again.
7. In small biopsies or specimens with small tumor areas, the 3 mm strategy may have to be reduced to either a 1 mm or 2 mm strategy. If a different strategy has been used for analysis, it must be noted in the comments section of the analysis worksheet.
B. Selection of Tumor Foci: 3 mm Strategy for Heterogeneous Tumors
III. Criteria for Microscope Analyses

C. Selection of Nuclei to Score

1. Select approximately 10 tumor nuclei for analysis in 2-3 microscope fields, in each of the 8 selected tumor areas.
   a. Select nuclei to be scored using the DAPI filter. Choose only nuclei that shows:
      1. Median to large diameter in comparison with other tumor nuclei in the specimen (to reduce effect of the nuclear truncation).
      2. Unambiguous borders (no overlapings, disruptions, etc).
   b) Confirm selection using the single or dual band pass filters. Verify that nuclei shows:
      1. Objectively interpretable signals.
      2. At least one signal for each target.

D. Imaging for Permanent Record

1. Document results capturing at least one image of each of the 8 areas using Z-stacking.
2. Annotate the location of the imaged fields using microscope coordinates or reference slide.
3. Image any and all atypical findings not addressed in these guidelines.
Selection of Nuclei to Score

* = selected nuclei
IV. Signal Enumeration and Recording

A. Counting Signals

1. Determine and record the number of EGFR (red) and CEP 7 (green) signals for each individual nucleus in the FISH analysis worksheet. Count signals according to the instructions below:
   a) Use **single red filter to enumerate red** signals and **single green filter to enumerate green** signals. Use dual red/green and triple red/green/blue filters to verify signal numbers.
   b) Scan the **focus through the entire depth** of the section to ensure that all signals are identified within each nucleus.
   c) Count as 1 signal any **doubles or triplets** that are physically connected (touching, linked by a tread) or adjacent (gap smaller than the diameter of the largest signal).
   d) Count as separate entities signals that are adjacent but separated by at least the diameter of the largest signal.

2. When nuclei do not exhibited clusters of signals, analyze at least **80 nuclei** per specimen. Report the assay as uninformative if the required number of nuclei is not available for analysis.

3. If clusters of the EGFR signal is present, proceed to (IV. B).
Counting Signals

Examples of clusters:
- cluster of 4 signals
- cluster of >15

1 signal
1 signal
1 signal
2 signals
2 signals
IV. Signal Enumeration and Recording

B. Defining Gene Amplification

1. Verify if consistently one or more copies of the EGFR signal is atypically large in tumor cells (brighter and larger than the CEP 7 signal) while showing the expected size in the non-tumor cells. Identify nuclei carrying this feature on the worksheet.

2. Verify presence of clusters of signals for one or both probes. If cells exhibit clusters of EGFR signals proceed as follows:
   a) if clusters are small (4-10 copies of signals) or very tight and enumerable, follow instructions provided in IV.A.1 and IV.A.2.
   b) if clusters are large (>10 copies), count the signals in only 30 nuclei. Enumerate as many signals as possible. If more than 15 copies are present, annotate “16” in the worksheet.
   c) if clusters are present only in some cells or some tumor areas, identify nuclei carrying this feature on the records.
1. Calculate for each specimen:
   a. % of cells showing ≤2, 3, ≥4 copies of the EGFR signal
   b. mean copy number per cell of EGFR signals and of CEP 7 signals
   c. ratio of the mean EGFR by mean CEP 7 signals
   d. % of cells with clusters of the EGFR gene with ≥4 signals or atypically large EGFR signals.